Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...

What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of ...

Moderna shares surged as much as 25 per cent to $207.37 in early trading following the release of the results, while Merck shares were up almost 1 per cent.

Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

Moderna's XBB.1.5 vaccine for those 12 and older. There are no monovalent XBB.1.5 vaccines registered for use in children aged six months to four years old.